Hallmarks of cancer as a synthesis of the theories
Rather than asking what starts cancer, Hanahan and Weinberg asked what every cancer ends up able to do: keep growing, ignore stop signals, avoid death, live forever, grow vessels, invade, rewire metabolism and hide from the immune system. Each update has absorbed a rival theory into the list, so the hallmarks read as the field's working synthesis rather than a theory of cause.
Overview
The claim. Whatever their origin, cancers converge on a shared set of acquired functional capabilities. The 2000 paper listed six: sustaining proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. The 2011 update added reprogramming energy metabolism and evading immune destruction, and named two enabling characteristics: genome instability and mutation, and tumour-promoting inflammation, with the tumour microenvironment as a full participant. Hanahan's 2022 paper added unlocking phenotypic plasticity, non-mutational epigenetic reprogramming, polymorphic microbiomes and senescent cells.
Who and when. Douglas Hanahan and Robert Weinberg, Cell 2000 and 2011; Hanahan alone in Cancer Discovery 2022. The papers are among the most cited in biology.
Evidence for. Each hallmark corresponds to a pathway and to a drug class that acts on it: CDK4/6 inhibitors for evading growth suppressors, BCL-2 inhibitors for resisting cell death, anti-VEGF antibodies for angiogenesis, checkpoint inhibitors for immune evasion, IDH inhibitors for metabolism, telomerase inhibition with imetelstat for replicative immortality. The framework organises teaching, drug discovery portfolios and, on this site, the mechanics atlas.
Evidence against and limits. Lazebnik's 2010 critique noted that benign tumours display most of the hallmarks and that only invasion and metastasis separate malignant from benign, so the list describes neoplasia more than cancer. Sonnenschein and Soto argue that the hallmarks are cell-centred and circular: they redescribe what cancer cells do without saying why a tissue produced them. The list is not predictive; it did not anticipate immunotherapy's clinical success (immune evasion entered only in 2011, after the first checkpoint trials) and it says nothing about the order of events or about prevention. Critics also observe that a list that grows with each update cannot be falsified.
Predictions that held or failed. Held: hallmark-directed drug classes exist for every core hallmark. Failed or qualified: the 2000 paper's expectation that anti-angiogenic therapy would be broadly curative was not met (bevacizumab adds months, not cures), and hallmark-directed monotherapies are rarely curative because tumours use the other hallmarks to compensate.
How it relates to the other theories. It sits at the end of the mainstream trunk (somatic mutation, drivers, clonal evolution) and has absorbed the microenvironment and inflammation view (2011), the immune surveillance view (2011), the metabolic view (2011) and the epigenetic and plasticity views (2022). The tissue organisation field theory and the atavistic theory remain outside it and criticise it.
Status: established as a framework and a vocabulary, not as a theory of cause. Its own authors call it a heuristic; its usefulness is in mapping mechanisms to medicines, which is how OnCo uses it.
Backbone ribbon from PDB 1BJ1. RCSB PDB 1BJ1. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Bevacizumab.
Cancer is now understood to change its identity and behaviour without new mutations, to be shaped by bacteria inside and around it, and to be helped along by ageing cells. This explains why some tumours escape targeted drugs by changing cell type and why gut bacteria affect immunotherapy response.
The hallmarks are the mental map most oncologists and researchers use to think about what cancer is and where drugs act. A newcomer can understand nearly every therapy as an attack on one hallmark: kinase inhibitors on proliferative signalling, checkpoint blockade on immune evasion, anti-VEGF drugs on angiogenesis.
Similar pages
not linked directly; found by shared links- TermAgeing tissue and clonal fields: cancer as a disease of old tissue
Shares Hallmark (2022): senescent cells, Epigenetic progenitor theory: cancer without a first mutation, Clonal evolution and the ecological view of cancer, Microenvironment and inflammation: tumours as wounds that do not heal and the tag theory.
- TermBioelectric theory of cancer (Levin)
Shares Tissue organisation field theory (Sonnenschein and Soto), Epigenetic progenitor theory: cancer without a first mutation, Somatic mutation theory of cancer, Theories of cancer: how the ideas connect and the tag theory.
- TermMechanical theory: stiffness, pressure and force as causes
Shares Tissue organisation field theory (Sonnenschein and Soto), Microenvironment and inflammation: tumours as wounds that do not heal, VEGF angiogenesis, Theories of cancer: how the ideas connect and the tag theory.
- TermSeed and soil hypothesis of metastasis (Paget)
Shares Clonal evolution and the ecological view of cancer, Microenvironment and inflammation: tumours as wounds that do not heal, Theories of cancer: how the ideas connect and the tag theory.
- TermDriver and passenger mutations: the refined somatic mutation theory
Shares Clonal evolution and the ecological view of cancer, Somatic mutation theory of cancer, Theories of cancer: how the ideas connect and the tag theory.
- PathwayCellular senescence
Shares Hallmark (2022): senescent cells, Telomere maintenance & replicative immortality, Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells, Intrinsic apoptosis (BCL-2 family).
- TermWarburg effect
Shares Atavistic theory: cancer as a reversion to an ancient programme, Hallmark: reprogramming cellular metabolism, Metabolic theory of cancer: from Warburg to oncometabolites, Cancer metabolism.
- PersonJudah Folkman
Shares Hallmark: inducing or accessing vasculature, Hallmarks of Cancer, Microenvironment and inflammation: tumours as wounds that do not heal, Bevacizumab.